Literature DB >> 19778765

Progressive multifocal leukoencephalopathy in HIV-1 infection.

Paola Cinque1, Igor J Koralnik, Simonetta Gerevini, Jose M Miro, Richard W Price.   

Abstract

Progressive multifocal leukoencephalopathy is caused by the JC polyomavirus (JCV) and is one of the most feared complications of HIV-1 infection. Unlike other opportunistic infections, this disease can present when CD4 counts are higher than those associated with AIDS and when patients are receiving combined antiretroviral therapy, either shortly after starting or, more rarely, during long term successful treatment. Clinical suspicion of the disease is typically when MRI shows focal neurological deficits and associated demyelinating lesions; however, the identification of JCV in cerebrospinal fluid or brain tissue is needed for a definitive diagnosis. Although no specific treatment exists, the reversal of immunosuppression by combined antiretroviral therapy leads to clinical and MRI stabilisation in 50-60% of patients with the disease, and JCV clearance from cerebrospinal fluid. A substantial proportion of patients treated with combined antiretroviral therapy develop inflammatory lesions, which can be associated with either a favourable outcome or clinical worsening. The reasons for variability in the natural history of progressive multifocal leukoencephalopathy and treatment responses are largely undefined, and more specific and rational approaches to management are needed.

Entities:  

Mesh:

Year:  2009        PMID: 19778765      PMCID: PMC2919371          DOI: 10.1016/S1473-3099(09)70226-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  108 in total

Review 1.  Immune restoration disease after antiretroviral therapy.

Authors:  Martyn A French; Patricia Price; Shelley F Stone
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

2.  Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRI.

Authors:  I Mader; U Herrlinger; U Klose; F Schmidt; W Küker
Journal:  Neuroradiology       Date:  2003-08-27       Impact factor: 2.804

3.  Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations.

Authors:  M Bergui; G B Bradac; K K Oguz; A Boghi; C Geda; G Gatti; D Schiffer
Journal:  Neuroradiology       Date:  2003-10-31       Impact factor: 2.804

4.  Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy.

Authors:  Cesare Giovanni Fedele; Maria Rosa Ciardi; Salvatore Delia; Gerardo Contreras; José Luis Perez; Maria De Oña; Elisa Vidal; Antonio Tenorio
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

5.  Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

Authors:  Wendy A Knowles; Pam Pipkin; Nick Andrews; Andrew Vyse; Philip Minor; David W G Brown; Elizabeth Miller
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

6.  Guidelines for the diagnosis and management of neurological complications of HIV infection.

Authors:  P Portegies; L Solod; P Cinque; A Chaudhuri; J Begovac; I Everall; T Weber; M Bojar; P Martinez-Martin; P G E Kennedy
Journal:  Eur J Neurol       Date:  2004-05       Impact factor: 6.089

7.  Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.

Authors:  W Royal; B Dupont; D McGuire; L Chang; K Goodkin; T Ernst; M J Post; D Fish; G Pailloux; H Poncelet; M Concha; L Apuzzo; E Singer
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

8.  Changing incidence of central nervous system diseases in the EuroSIDA cohort.

Authors:  Antonella d'Arminio Monforte; Paola Cinque; Amanda Mocroft; Frank-Detlev Goebel; Francisco Antunes; Christine Katlama; Ulrik Stenz Justesen; Stefano Vella; Ole Kirk; Jens Lundgren
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

9.  Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy.

Authors:  Jacques Gasnault; Mufide Kahraman; Marie Ghislaine de Goër de Herve; Deniz Durali; Jean-François Delfraissy; Yassine Taoufik
Journal:  AIDS       Date:  2003-07-04       Impact factor: 4.177

10.  A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.

Authors:  Renaud A Du Pasquier; Marcelo J Kuroda; Yue Zheng; Jims Jean-Jacques; Norman L Letvin; Igor J Koralnik
Journal:  Brain       Date:  2004-06-23       Impact factor: 13.501

View more
  66 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 2.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

3.  Case files of the New York City poison control center: paradichlorobenzene-induced leukoencephalopathy.

Authors:  Stephanie H Hernandez; Sage W Wiener; Silas W Smith
Journal:  J Med Toxicol       Date:  2010-06

Review 4.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 5.  Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy.

Authors:  Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili
Journal:  Rev Med Virol       Date:  2015-12-14       Impact factor: 6.989

Review 6.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

7.  Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.

Authors:  Angela Matinella; M Lanzafame; M A Bonometti; A Gajofatto; E Concia; S Vento; S Monaco; S Ferrari
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

8.  JC virus infection of the brain.

Authors:  A K Bag; J K Curé; P R Chapman; G H Roberson; R Shah
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

9.  Unmasking of PML by HAART: unusual clinical features and the role of IRIS.

Authors:  Navdeesh Sidhu; J Allen McCutchan
Journal:  J Neuroimmunol       Date:  2009-12-04       Impact factor: 3.478

10.  Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.

Authors:  Lars Hagberg; Paola Cinque; Magnus Gisslen; Bruce J Brew; Serena Spudich; Arabella Bestetti; Richard W Price; Dietmar Fuchs
Journal:  AIDS Res Ther       Date:  2010-06-03       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.